Intermittent normobaric hypoxia therapy for COVID-19 survivors: a promising approach to recovery

Abstract

This groundbreaking study delves into the transformative potential of Intermittent Normobaric Hypoxia Therapy (INHT) in a targeted cohort of 50 young adult COVID-19 survivors, aged 18 to 24 years. Through comprehensive pre- and post-INHT spirometry assessments, our research uncovers the nuanced respiratory benefits of this innovative therapy. The results showcase significant improvements in key spirometry parameters, emphasizing INHT's pivotal role in restoring lung function and fostering holistic respiratory well-being post-COVID-19